Year 2022 / Volume 114 / Number 6
Letter
Infliximab-induced hypoglycemia, a rare but relevant side effect

364-365

DOI: 10.17235/reed.2022.8460/2021

Lucía Zabalza, Joaquín de Carlos, Iranzu Ezcurra, María Rullán, Alfonso Elosua, Saioa Rubio, Lluis Forga, Cristina Rodríguez,

Abstract
Tumor necrosis factor (TNF) inhibitors are part of the therapeutic arsenal for many immune-mediated diseases and, especially in inflammatory bowel disease (IBD), have led to a change in the management of this disease.
Share Button
New comment
Comments
No comments for this article
References
1. Shivaji UN, Sharratt CL, Thomas T, et al. Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2019 Mar;49(6):664-680. doi: 10.1111/apt.15097. Epub 2019 Feb 8. PMID: 30735257.
2. Wambier CG, Foss-Freitas MC, Paschoal RS, et al. Severe hypoglycemia after initiation of anti-tumor necrosis factor therapy with etanercept in a patient with generalized pustular psoriasis and type 2 diabetes mellitus. J Am Acad Dermatol. 2009 May;60(5):883-5. doi: 10.1016/j.jaad.2008.10.009. PMID: 19389539.
3. Boulton JG, Bourne JT. Unstable diabetes in a patient receiving anti-TNF-alpha for rheumatoid arthritis. Rheumatology (Oxford). 2007 Jan;46(1):178-9. doi: 10.1093/rheumatology/kel322. Epub 2006 Sep 23. PMID: 16998233.
4. Mah JY, Teng J, Gilfillan C. Tumour necrosis factor-alpha inhibitor induced recurrent symptomatic hypoglycaemia. Intern Med J. 2019 Nov;49(11):1460-1461. doi: 10.1111/imj.14636. PMID: 31713334.
5. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993 Jan 1;259(5091):87-91. doi: 10.1126/science.7678183. PMID: 7678183.
Related articles

Letter

Hepatosplenic T-cell lymphoma and inflammatory bowel disease

DOI: 10.17235/reed.2023.9472/2023

Original

Megacolon in inflammatory bowel disease: response to infliximab

DOI: 10.17235/reed.2020.6394/2019

Citation tools
Zabalza L, de Carlos J, Ezcurra I, Rullán M, Elosua A, Rubio S, et all. Infliximab-induced hypoglycemia, a rare but relevant side effect . 8460/2021


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1327 visits.
This article has been downloaded 212 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 19/11/2021

Accepted: 24/01/2022

Online First: 04/02/2022

Published: 07/06/2022

Article revision time: 54 days

Article Online First time: 77 days

Article editing time: 200 days


Share
This article has been rated by 2 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology